Interventions for preventing oral mucositis for patients with cancer receiving treatment

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Worthington, Helen V ^a   Clarkson, J E ^b   Eden, O B ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NONE

Author keywords

Antifungal agents *therapeutic use ; Antineoplastic agents *adverse effects ; Candidiasis, oral etiology; *prevention control ; Cryotherapy; Drugs, Chinese herbal therapeutic use ; Ice; Mouth mucosa

Indexed keywords

ACICLOVIR; ALLOPURINOL; ALOE VERA EXTRACT; AMIFOSTINE; ANTIBIOTIC AGENT; BENZYDAMINE; BETA CAROTENE; CALCIUM PHOSPHATE; CHAMOMILE; CHINESE DRUG; CHLORHEXIDINE; CLARITHROMYCIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE; HYDROLASE; ISEGANAN; KERATINOCYTE GROWTH FACTOR; MISONIDAZOLE; PENTOXIFYLLINE; PILOCARPINE; PLACEBO; POVIDONE; PREDNISONE; PROPANTHELINE BROMIDE; PROSTAGLANDIN; SUCRALFATE; ZINC SULFATE; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CLOTRIMAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; ANTIFUNGAL AGENT;

ALOE VERA; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG DOSAGE FORM; DYSPHAGIA; HEAD AND NECK CANCER; HEALTH CARE COST; HONEY; HOSPITALIZATION; HUMAN; LEUKEMIA; MOUTHWASH; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SOLID TUMOR; ANALGESIA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DATA EXTRACTION; DRUG ABSORPTION; DRUG EFFICACY; ERADICATION THERAPY; INFECTION; INFORMATION PROCESSING; INTERVENTION STUDY; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RESEARCH; NEOPLASM; PATIENT CARE; PRESCRIPTION; RISK ASSESSMENT; THRUSH; TREATMENT OUTCOME; META ANALYSIS;

ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; CLOTRIMAZOLE; HUMANS; KETOCONAZOLE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 37249022122     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000978.pub3     Document Type: Review

References (335)

1. Ahmed 1993 {published data only} Ahmed T, Engelking C, Szalyga J, Helson L, Coombe N, Cook P, et al.Propantheline prevention of mucositis from etoposide. Bone Marrow Transplantation 1993;12(2):131-2.
2. Anderson 1998 {published and unpublished data} Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998;83(7):1433-9.
3. Antonadou 2002 {published data only} Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. International Journal of Radiation Oncology, Biology and Physics 2002;52(3):739-47.
4. Attal 1993 {published data only} Attal M, Huguet F, Rubie H, Charlet J-P, Schlaifer D, Huynh A, et al.Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective, randomized trial. Blood 1993;82(3):732-6.
5. Biswal 2003 {published data only} Biswal BM, Zakaria A, Ahmad NM. Topical application of honey in the management of radiation mucositis. A preliminary study. Supportive Care in Cancer 2003;11(4):242-8.
6. Biswal BM, Zakaria A, Nik Min A. Topical application of honey in the management of radiation mucositis: A randomised study. International Journal of Cancer 2002;Supp 13:480 (Abs 1109).
7. Borowski 1994 {published data only} Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. European Journal of Cancer Part B, Oral Oncology 1994;30B(2):93-7.
8. Bourhis 2000 {published data only} *Bourhis J, De Crevoisier R, Abdulkarim B, Deutsch E, Lusinchi A, Luboinski B, et al.A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. International Journal of Radiation Oncology, Biology and Physics 2000;46(5):1105-8.
9. Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Seminars in Oncology 2002;29(6):Supp 19 61-2.
10. Brizel 2000 {published data only} Brizel DM, Wasserman TH, Henke H, Strnad V, Rudat V, Monnier A, et al.Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology 2000;18(19):3339-45.
11. Bubley 1989 {published data only} Bubley GJ, Chapman B, Chapman SK, Crumpacker CS, Schnipper LE. Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions. Antimicrobial Agents and Chemotherapy 1989;33(6):862-5.
12. Buentzel 2006 {published data only} Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. International Journal of Radiation Oncology, Biology, Physics 2006;64(3):684-91.
13. Buntzel 1998 {published data only} Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel J. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: Preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation 2001;19(2):107-13.
14. Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Seminars in Oncology 2002;29(6):Supp 19 61-2.
15. Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology 2002;12(1 (Supp 1)):4-13.
16. Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology 1998;9(5):505-9.
17. *Buntzel J, Schuth J, Kuttner K, Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer 1998;6(2):155-60.
18. Cartee 1995 {published data only} Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, Affronti ML, et al.Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995;7(5):471-7.
19. Carter 1999 {published data only} Carter DL, Hebert ME, Smink K, Leopold KA, Clough RL, Brizel DM. Double blind randomized trial of sucralfate vs placebo radial radiotherapy for head and neck cancers. Head and Neck 1999;21(8):760-6.
20. Cascinu 1994 {published and unpublished data} Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. European Journal of Cancer Part B, Oral Oncology 1994;30B:234-6.
21. Castagna 2001 {published data only} Castagna L, Benhamou E, Pedraza E, Luboinski M, Forni M, Brandes I, et al.Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. Annals of Oncology 2001;12(7):953-5.
22. Cengiz 1999 {published data only} Cengiz M, Ozyar E, Ozturk D, Akyol F, Atahan IL, Hayran M. Sucralfate in the prevention of radiation-induced oral mucositis. Journal of Clinical Gastroenterology 1999;28(1):40-3.
23. Cerchietti 2006 {published data only} Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, et al.Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics 2006;65(5):1330-7.
24. Crawford 1999 {published data only} Crawford J, Tomita DK, Mazanet R, Glaspy J, Ozer H. Reduction of oral mucositis by filgrastim(r-metHuG- CSF) in patients receiving chemotherapy. Cytokines, Cellular and Molecular Therapy 1999;5(4):187-93.
25. Damon 2004 {published data only} Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, et al.Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemotherapy and Pharmacology 2004;53(6):468-74.
26. Dazzi 2003 {published data only} Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, Leoni M, et al.Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Annals of Oncology 2003;14(4):559-63.
27. Dazzi C, Cariello A, Monti M, Giovanis P, Vertogen B, Nanni O, et al.Prophylaxis with GM-CSF mouthwash does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high dose chemotherapy with autogous PBPC rescue: A double blind randomized placebo-controlled study. Annals of Oncology 2002;13 (Supp 5):167 (Abs 617).
28. Dickson 2000 {published data only} Coghlin Dickson TM, Wong RM, Offrin RS, Shizuru JA, Johnston LJ, Hu WW, et al.Effect of oral glutamine supplementation during bone marrow transplantation. Journal of Parenteral and Enteral Nutrition 2000;24(2):61-6.
29. Dodd 1996 {published and unpublished data} Dodd MJ, Larson PJ, Dibble SL, Miaskowski C, Greenspan D, MacPhail L, et al.Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncological Nursing Forum 1996;23(6):921-7.
30. Dozono 1989 {published data only} Dozono H, Nakamura K, Motoya T, Nakamura S, Shinmura R, Miwa K, et al.Prevention of stomatitis induced by anti-cancer drugs. Gan-to-kagaku-ryoho 1989;16(10):3449-51.
31. Duenas 1996 {published and unpublished data} Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, Gallardo-Rincon D, Lara-Medina F, Aguilar-Ponce L, et al.Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplantation 1996;17(5):809-12.
32. El Sayed 2002a {published data only} Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J, et al.Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head & Neck 2005;27(5):421-8.
33. *El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M, et al.Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. Journal of Clinical Oncology 2002;20(19):3956-63.
34. Elad 2006 {published data only} Elad S, Ackerstein A, Bitan M, Shapira MY, Resnick I, Gesundheit B, et al.A prospective, double-blind phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplantation 2006;37(8):757-62.
35. Erlichman 1988 {published data only} Erlichman C. Fluorouracil and leucovorin for metastatic colorectal cancer. Journal of Chemotherapy 1990;2(S1):38-40.
36. *Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folonic acid in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology 1988;6(3):469-75.
37. Ertekin 2004 {published data only} Ertekin MV, Koc M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. International Journal of Radiation Oncology, Biology, Physics 2004;58(1):167-74.
38. Ferretti 1988 {published and unpublished data} Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. Journal of American Dental Association 1987;114(4):461-7.
39. *Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplantation 1988;3(5):483-93.
40. Ferretti 1990 {published and unpublished data} Ferretti GA, Raybould TP, Brown AT, Macdonal JS, Greenwood M, Maruyama Y, et al.Chlorhexidine prophylaxis for chemotherapy- and radiotherapy- induced stomatitis: a randomised double-blind trial. Oral Surgery, Oral Medicine, Oral Pathology 1990;69(3):331-8.
41. Fidler 1996 {published data only} Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL, et al.Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 1996;77(3):522-5.
42. Foote 1994 {published data only} Foote RL, Loprinzi CL, Frank AR, O'Fallon JR, Gulavita S, Tewfik HH, et al.Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. Journal of Clinical Oncology 1994;12(12):2630-3.
43. Franzen 1995 {published data only} Franzen L, Henriksson R, Littbrand B, Zackrisson B. Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region. Acta Oncologica 1995;34(2):219-23.
44. Freytes 2004 {published data only} Freytes CO, Ratanatharathorn V, Taylor C, Abboud C, Chesser N, Restrepo A, et al.Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clinical Cancer Research 2004;10(24): 8318-24.
45. Giles 2003a {published data only} Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, et al.A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). Leukemia & Lymphoma 2003;44(7):1165-72.
46. Giles 2004 {published data only} Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, et al.A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leukemia Research 2004;28(6):559-65.
47. Gujral 2001 {published data only} Gujral MS, Patnaik PM, Kaul R, Parikh HK, Conradt C, Tamhankar CP, et al.Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemotherapy Pharmacology 2001;47:S23-S28.
48. Hartmann 2001 {published data only} Hartmann JT, von Vangerow A, Fels LM, Knop S, Stolte H, Kanz L, et al.A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. British Journal of Cancer 2001;84(3): 313-20.
49. Huang 2000 {published data only} Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, et al.Oral glutamine to alleviate radiation-induced oral mucositis: A pilot randomized trial. International Journal of Radiation Oncology, Biology and Physics 2000;46(3):535-9.
50. Huang 2003 {published data only} Huang GX, Zhao C, Han F, Zhang B, Qiu HJ, Xu BP, et al.[Clinical study in prophylactic use of chinesemedicine to prevent chemoradiotherapy induced mucositis in nasopharyngeal carcinoma]. Ai Zheng 2003;22(10):1084-7.
51. Hwang 2004 {published data only} Hwang WY, Koh LP, Ng HJ, Tan PH, Chuah CT, Fook SC, et al.A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 2004;34(1):51-6.
52. Ifrah 1999 {published data only} Ifrah N, Witz F, Jouet JP, Francois S, Lamy T, Linassier C, et al.Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. American Cancer Society 1999;86(8):1496-505.
53. Jebb 1994 {published and unpublished data} Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D, et al.5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. British Journal of Cancer 1994;70(4):732-5.
54. Karacetin 2004 {published data only} Karacetin D, Yucel B, Leblebicioglu B, Aksakal O, Maral O, Incekara O. A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer. Journal of B.U.ON 2004;9(1):23-6.
55. Katano 1995 {published data only} Katano M, Nakamura M, Matsuo T, Iyama A, Hisatsugu T. Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis. Surgery Today 1995;25(3):202-6.
56. Kaul 1999 {published data only} *Kaul R, Mishra BK, Sutradar P, Choudhary V, Gujral MS. The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers - a clinical phase-III randomized trial. Indian Journal of Cancer 1999;36(2-4):141-8.
57. Kaul RVC. To evaluate the effect of Wobe mugos hydrolytic enzyme therapy on inflammation induced by external radiotherapy in patients of head and neck cancers. Bahrain Medical Bulletin 2001;23(3):116-8.
58. Koukourakis 2000 {published data only} Koukourakis MI, Kyria G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromonaolaki A, et al.Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. Journal of Clinical Oncology 2000;18(11 June):2226-33.
59. Labar 1993 {published data only} Labar B, Mrsic M, Pavletic Z, Bogdanic V, Nemet D, Aurer I, et al.Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplantation 1993;11(5):379-82.
60. Leborgne 1997 {published data only} Leborgne JH, Leborgne F, Zubizarreta E, Ortega B, Mezzera J. Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiotherapy and Oncology 1997;47(2):145-8.
61. Lee 1989 {published data only} Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). International Journal of Radiation Oncology, Biology, Physics 1989;16(2):465-70.
62. Lilleby 2006 {published data only} Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, et al.A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 2006;37(11):1031-5.
63. Lockhart 2005 {published data only} Lockhart PB, Brennan MT, Kent ML, Packman CH, Norton HJ, Fox PC, et al.Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplantation 2005;35(7):713-20.
64. Loprinzi 1990 {published and unpublished data} Loprinzi CL, Cainflone SG, Dose AM, Etzell PS, Burnham NL, Therneau TM, et al.A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer 1990;65(8):1879-82.
65. Mahood 1991 {published data only} Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Thereau TM, et al.Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. Journal of Clinical Oncology 1991;9(3):449-52.
66. Makkonen 1994 {published data only} Makkonen TA, Bostrom P, Vilja P, Joensuu H. Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study. International Journal of Radiation Oncology, Biology and Physics 1994;30(1):177-82.
67. Makkonen 2000 {published data only} Makkonen TA, Minn H, Jekunen A, Vilja P, Tuominen J, Joeensuu H. Granulocyte Macrophage-colony stimulating factor (GMCSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study. International Journal of Radiation Oncology, Biology and Physics 2000;46(3):525-34.
68. Meropol 2003 {published data only} Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al.Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. Journal of Clinical Oncology 2003;21(8): 1452-8.
69. Mills 1988 {published data only} Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. British Journal of Cancer 1988;57(4):416-7.
70. Nemunaitis 1995 {published data only} Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, et al.Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(6):949-54.
71. Niibe 1985 {published data only} Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y, et al.An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.1. Head and neck tumors. Nippon-gan-chiryo-gakkai- shi 1985;20(5):984-93.
72. Nottage 2003 {published data only} Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, et al.Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer 2003;11(1):41- 7.
73. Oberbaum 2001 {published data only} *Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS, et al.A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. American Cancer Society 2001;92(3):684-90.
74. Oberbaum M, Yaniv I, Ben-Gal Y, Stein J, Ben-Zvi N, Freedman LS, et al.A randomized, controlled clinical trial of the homoeopathic medication Traumeel S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation. Biologische Medizin 2002;31(1):25-31.
75. Okuno 1999 {published data only} Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D, et al.Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 1999;22(3):258-61.
76. Papas 2003 {published data only} Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplantation 2003;31(8):705- 12.
77. Pfeiffer 1990 {published data only} Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. Acta Oncologica 1990;29(2):171-3.
78. Pillsbury 1986 {published data only} Pillsbury HC 3rd, Webster WP, Rosenman J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Archives of Otolaryngology - Head & Neck Surgery 1986;112(5):552-3.
79. Pitten 2003 {published data only} Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection 2003;53(4):283-91.
80. Prada 1987 {published data only} Prada A, Chiesa F. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy. International Journal of Tissue Reaction 1987;9(2):115-9.
81. Rahn 1997 {published data only} Adamietz IA, Rahn R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis of radiochemotherapy-induced mucositis. Efficacy of prophylactic oral rinsing with povidone iodine solution [Pophylaxe der radiochemotherapeutisch bedingten mukositis]. Stranhlentherapie und Onkologie 1998;174(3):149-55.
82. Adamietz IA, Rhan R, Bottcher HD, Schafer V, Reimer K, Fleischer W. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Supportive Care in Cancer 1998;6(4):373-7.
83. *Rahn R, Adamietz IA, Boettcher HD, Schaefer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 1997;195(Suppl 2):57-61.
84. Rahn R AI, Bottcher HD, Reimer K, Fleischer W. PVP-iodine solution as a mucositis prophylaxis by radiotherapy. Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichtschirurgie 1996;20(3):137-9.
85. Rocke 1993 {published data only} Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, et al.A randomized clinical trial of two different durations or oral cryotherapy for prevention of 5-fluorouracil- related stomatitis. Cancer 1993;72(7):2234-8.
86. Saarilahti 2002 {published data only} Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. International Journal of Radiation Oncology Biology and Physics 2002;54(2):479-85.
87. Scarantino 2006 {published data only} Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, et al.Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. The Journal of Supportive Oncology 2006;4(5):252-8.
88. Scherlacher 1990 {published data only} Scherlacher A, Beaufort-Spontin F. [Radiotherapy of head-neck neoplasms: prevention of inflammation of themucosa by sucralfate treatment]. [German]. HNO 1990;38(1):24-8.
89. Schneider 1999 {published data only} Schneider SB, Nishimura RD, Zimmerman RP, Tran L, Shiplacoff J, Tormey M, et al.Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double blind, placebo-controlled trial. Cytokines, Cellular and Molecular Therapy 1999;5(3):175-80.
90. Shenep 1988 {published and unpublished data} Shenep JL, Kalwinsky DK, Hutson PR, George SL, Dodge RK, Blankenship KR, et al.Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. Journal of Pediatrics 1988;113(4):758-63.
91. Shieh 1997 {published data only} Shieh SH, Wang ST, Tsai ST, Tseng CC. Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncology 1997;33(1):36-41.
92. Spencer 2005 {published data only} Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J, et al.Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation 2005;35(10):971-7.
93. Spielberger 2004 {published data only} Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al.Palifermin for oral mucositis after intensive therapy for hematologic cancers. The New England Journal of Medicine 2004;351(25):2590-8.
94. Spijkervet 1989 {published data only} Spijkervet FKL, van Saene HK, Panders AK, Vermey A, van Saene JJ, Mehta DM, et al.Effects of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surgery, Oral Medicine, Oral Pathology 1989;67(2):154-61.
95. Stokman 2003 {published data only} Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. British Journal of Cancer 2003;88(7):1012-6.
96. Su 2003 {published data only} Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J, et al.Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. International Journal of Radiation, Oncology, Biology and Physics 2004;60(1 Sept):171-7.
97. Symonds 1996 {published data only} Symonds RP, McIlroy P, Khorrami J, Pyper E, Alcock SR, McCallum I, et al.The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. British Journal of Cancer 1996;74(2):312-7.
98. Trotti 2004 {published data only} *Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al.A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. International Journal of Radiation Oncology, Biology and Physics 2004;58(3):674-81.
99. Trotti A, Garden AS, Warde P, Symonds P, Langer C, Fleming T, et al.Phase III trial of iseganan HCL oral solution (iseganan) for reducing oral mucositis severity in patients receiving radiotherapy for head and neck malignancies (PROMPT-RT). Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2002:(Abs No 908).
100. van der Lelie 2001 {published data only} van der Lelie H, Thomas BL, van Oers RH, Ek-Post M, Sjamsoedin SA, van Dijk-Overtoom ML, et al.Effect of locally applied GMCSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Annals of Hematology 2001;80(3):150-4.
101. Vokurka 2005 {published data only} Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D, et al.The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT - results of a randomized multicentre study. Supportive Care in Cancer 2005;13(7):554-8.
102. Wahlin 1989 {published and unpublished data} Wahlin YB. Effects of chlorhexidine mouthrinse on the oral health in patients with acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology 1989;68(3):279-87.
103. Wang 2002a {published data only} Wang J. Effect on Chinese herbs decoction gargling to treat and to prevent chemotherapy caused stomatitis. Chinese Nursing Research 2002;16(10):578-9.
104. Wijers 2001 {published data only} Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD, et al.Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: A placebo-controlled double-blind randomized study. International Journal of Radiation Oncology, Biology and Physics 2001;50(2):343-52.
105. Yuen 2001 {published data only} Yuen KY, Woo PCY, Tai JW, Lie AK, Luk J, Liang R. Effects of clarithromycin on oral mucositis in bone marrow transplant recipients. Haematologica 2001;86(5):554-5.
106. Adamietz 1997 Adamietz IA, Rahn R, Bottcher HD, Reimer K, Fleischer W. Prophylaxis of radiation induced oral mucositis with povidone iodine. Supportive Care in Cancer 1997;5 Suppl:165 (Abs No 48).
107. Altmann 1999 Altmann S Hoffmanns H. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. [German]. Strahlentherapie und Onkologie 1999;175(Suppl 4):30-3.
108. Andersen 1987 Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncologica 1987;26(6):433-6.
109. Anderson 1998b Anderson PM, Ramsay NKC, Shu XO, Rydholm N, Rogosheske J, Nicklow R, et al.Effect of low dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplantation 1998;22(4):339-44.
110. Antin 2002 Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, et al.A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation 2002;29(5):373- 7.
111. Antonadou 1998 Antonadou D, Athanassiou E, Synodinou M, Koliarakis N, Panoussaki K, Karageorgis P, et al.Evaluation of the efficacy of granulocyte macrophage colony stimulating factor (GM-CSF) in the prevention of radiation induced mucositis [abstract]. Radiotherapy Oncology 1998;48(S1): S39.
112. Apaydin 1996 Apaydin A, Karadeniz AN, Aysigi G, Blige N. The effect and therapeutical use of benzydamine HCL on radiation-induced oral cavity and oropharyngeal mucositis. Medical Bulletin Istanbul 1996;29:1:59-63.
113. Aquino 2005 Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH, et al.A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplantation 2005;36(7):611-6.
114. Ardizzoni 2002 Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al.Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. Journal of Clinical Oncology 2002;20(19):3947-55.
115. Awada 2002 Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, et al.An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer 2002;38(6):773-8.
116. Awada 2004 Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, et al.Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-Cancer Drugs 2004;15(5):499-502.
117. Awidi 2001 Awidi A, Homsi U, Kakail RI, Mubarak A, Hassan A, Kelta M, Martinez P, et al.Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. European Journal of Cancer 2001;37(16):2010- 4.
118. Awwad 2002 Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM, et al.Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cnacer: influence of proliferation. British Journal of Cancer 2002;86(4):517-23.
119. Barasch 1995 Barasch A, Peterson DE, Tanzer JM, D'Ambrososio JA, Nuki K, Schubert MM, et al.Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995;76(12):2550-6.
120. Bensadoun 1995 Bensadoun R, Cowen D, Nguyen TD, Ciais G, Franquin JC, Dassonville O, et al.Low energy laser in the prevention of radiation-induced mucositis: A phase III randomized multicentric study in patients with head and neck cancer. Fifth International Congress on Anti-Cancer Chemotherapy. 1995.
121. Bensadoun 1999 Bensadoun R, Franquin J, Benezery K, Ciais G, Tardieu C, Dejou J, et al.Low energy He/Ne laser in the prevention of radiation induced mucositis: A multicenter phase III double blind study for patients with head and neck cancer. Proceedings of ASCO. 1999.
122. Bensadoun RJ, Ciais G, Darcourt V, Franquin JC, Cheynet C, Cowen D, et al.Low energy laser in the prevention of radiation induced mucositis: a phase II randomized multicentre study for patients with head and neck cancer. Supportive Care in Cancer 1999;7:SO-13.
123. *Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M, et al.Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicentre phase III randomized study in patients with head and neck cancer. Supportive Care in Cancer 1999;7(4):244-52.
124. Bensadoun 2006 Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, et al.French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). International Journal of Radiation Oncology, Biology, Physics 2006;64(4):983-94.
125. Bentzen 2001 Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiotherapy Oncology 2001;60(2):123-35.
126. Bergmann 1995 Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 1995;6(310):116-72.
127. Bleehen 1996 Bleehen NM, Girling DJ, Hopwood P, Lallemand G, Machin D, Stephens RJ, et al.Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406-13.
128. Bolwell 2004 Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al.A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 2004;34(7):621-5.
129. Bourhis 2006 Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al.Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. Journal of Clinical Oncology 2006;24(18):2873-8.
130. Braaksma 2002 Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology 2002;29(6 Supp 19):63-70.
131. Buentzel 1999 Buentzel J, Glatzel M, Weinaug R, Schuth J, Kuettner K, Froehlich D. Amifostine in combined radio- and chemomodalities for head and neck cancer. European Journal of Cancer 1999;35(Suppl 4):363 (Abs No 1472).
132. Calais 1998 Calais GM, Alfonsi E, Bardet C, Sire H, Bourgeois C, Bergerot B, et al.Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III andf IV oropharynx carcinoma (ARCORO). Preliminary results of the 94.01 study from the French Group of radiation oncology for head and neck cancer (GORTEC). Proceedings of Annual Meeting of the American Society of Clinical Oncology. 1998:(Abs No 1484).
133. Calais 2000 Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al.[Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. Bulletin du Cancer 2000;87 Spec No:48-53.
134. Calais 2004 Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B, et al.Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. International Journal of Radiation, Oncology, Biology and Physics 2004;58(1 Jan):161-6.
135. Cassidy 2002 Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al.First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Annals of Oncology 2002;13(4):566-75.
136. Cella 2003 Cella D, Pulliam J, Fuchs H, Miller C, Hurd D, Wingard JR, et al.Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003;98(2):406-12.
137. Cheng 2001 Cheng KK Molassiotis A, Chang AM, Wai WC, Cheung SS. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. European Journal of Cancer 2001;37(16):2056-63.
138. Cheng 2002 Cheng KKF, Malassiotis A, Chang AM. An oral care protocol intervention to prevent chemotherapy-induced oral mucositis in paediatric cancer patients: a pilot study. European Journal of Oncology Nursing 2002;6(2):66-74.
139. Cheng 2003 Cheng KK, Chang AM. Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 2003;26(6):476-84.
140. Cheng 2004a Cheng KK. Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. European Journal of Oncology Nursing 2004;8(4):341-9.
141. Cheng 2004b Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. European Journal of Cancer 2004;40(8):1208-16.
142. Chi 1995 Chi KH, Chen CH, Chan WK, Yen SH, Liang MJ, Chou KC, et al.Effect of granulocyte-macrophage colony-stimulating factor (GH-CFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. Proceedings of Annual Meeting American Society of Clinical Oncology. 1994; Vol. 13:A1469.
143. *Chi KH, Chen SY, Chan WK, Yen SH, Liang MJ, Chou KC, et al.Effect of granulocyte-macrophage colony-stimulating factor (GHCFS) on oral mucositis in head and neck cancer patients after cisplatin, 5-FU and leucovorin chemotherapy. Journal of Clinical Oncology 1995;13(10):2620-8.
144. Collova 2004 Collova E, Castagna L, Nozza A, Perfetti V, Patrone F, Danova M, et al.New approaches for reduction of oral mucositis in patients undergoing high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplantation 2004;33(Suppl 1):S323-S4.
145. Colombat 1995 Colombat P, Colin B. Comparison of fluconazole and amphotericin B in the prevention of mucositis in patients with long term aplasia. Bone Marrow Transplantation 1995;15:178.
146. Costa 1999 Costa EMMB, Pinto LP, Fernandes MZ, Costa ALL. Preventing oral complications in leukemic children submitted to chemotherapy. Journal of Dental Research 1999;78:1021 (Abs No B-220).
147. Costa 2003 Costa EM, Fernandes MZ, Quinder LB, de Souza LB, Pinto LP. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesquisa Odontologica Brasileira 2003;17(2):147-50.
148. Cowen 1997 Cowen D, Tardieu C, Resbeut M, Hannoun-Levi JM, Alzieu C, Schubert M, et al.Low energy helium-neon laser presents oral mucositis after high-dose chemo-radiotherapy: results of a double-blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1996;36(1S):264 (A1041).
149. *Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C, et al.Low energy Helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. International Journal of Radiation Oncology, Biology and Physics 1997;38(4):697-703.
150. Crawford 1994 Crawford J, Glaspy J, Vincent M, Tomita D, Mazanet R. Effect of filgrastim (r-metHug-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin and etoposide, CAE). Proceedings of Annual Meeting of American Society Clinical Oncology. 1994; Vol. 13:(AbsNo A1523).
151. Crispino 1997 Crispino SP, Olmi C, Fallai F, Rossi S, Marsoni A, Tinazzi M, et al.Conventional radiotherapy (RT) versus accelerated hyperfractionated RT versus conventional RT and concomitant chemotherapy in locally advanced oropharyngeal carcinoma (ORO-93/01). Proceedings of the American Society of Clinical Oncology. 1997.
152. Cruz 1997 Cruz J, Fonseca E, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P, et al.Randomized trial of cisplatin (P) plus 5-fluorouracil (F) with or without folinic acid in locally advanced head and neck cancer (LAHNC). Proceedings of the European Cancer Conference. 1997:(Abs No 854).
153. Cunningham 1995 Cunningham D, Zalcberg JR, Rath U, Olver I, van Cutsem EV, Sevensson C, et al.'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. European Journal of Cancer 1995;31A(12):1945-54.
154. De Boer 2002 De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S, et al.A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Annals of Oncology 2002;13(6):889-94.
155. Decker-Baummann 1999 Decker-Baumann C, Buhl K, Frohmuller S, von Herbay A, Dueck M, Schlag PM. Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. European Journal of Cancer 1999;35(2):202-7.
156. Denham 1999 Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, et al.Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?. Radiotherapy Oncology 1999;52(2):157-64.
157. Djuric 2006 Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Supportive Care in Cancer 2006;14(2):137-46.
158. Dobrowsky 1998 Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R, et al.Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1998;42(4):803-6.
159. Doroshow 1987 Doroshow JH, Berthtand M, Newman E, Multhauf P, Leong L, Blayney D, et al.Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monographs 1987;5:171-4.
160. Dudjak 1987 Dudjak LA. Mouth care for mucositis due to radiation therapy. Cancer Nursing 1987;10(3):131-40.
161. Edelman 1998 Edelman MJ, Gandara Dr, Perez EA, Lau D, Lauder I, Turrell C, et al.Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Investigational New Drugs 1998;16(1):69-75.
162. Eisen 2003 Eisen D, Essel J, Broun ER, Sigmund D, DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation 2003;31(1):51-5.
163. El-Sayed 2000 El-Sayed S, Nabid A, MacKenzie R, Gelinas M, Hay J, Shelley, et al.Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. Proceedings of the 42nd Annual Meeting of the American Society of Therapeutic Oncology. 2000; Vol. 321:(Abs No 2115).
164. El-Sayed 2002b El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E. A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head & Neck 2002;24(1):6- 15.
165. Epstein 1986 Epstein JB, Stephenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surgery, Oral Medicine, Oral Pathology 1986;62(2):145-8.
166. Epstein 1989 Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse. International Journal of Radiation Oncology, Biology and Physics 1989;16(6):1571-5.
167. Epstein 1992 Epstein JB, Vickars L, Spinalli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1992;73(6):682-9.
168. Epstein 1994 Epstein JB, Wong FLW. The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1994;28(3):693-8.
169. Epstein 1999 Epstein J, Silverman S Jr, Pagerino D, Lockhart P, Schubert M, Crockett R. Benzydamine HCL for prophylaxis of irradiation induced oral mucositis: a randomized double-blind, multicenter study. Supportive Care in Cancer 1999;7 Suppl:169 (Abs No O-18).
170. Epstein 2001 Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN, et al.Benzydamine HCI for prophylaxis of radiation-induced oral mucositis. Cancer 2001;92(4):875-85.
171. Erkisi 1996 Erkisi M, Erkurt E, Ozbarlas S, Burgut R, Doran F, Seyrek E. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Journal of Chemotherapy 1996;8(3):224-8.
172. Etiz 1998 Etiz M, Erkal HS, Serin M, Kucuk B, Hepari A, Tulunay O, et al.Clinicohistopathological evaluation of effectiveness of sucralfate in prevention of severe radiation-induced mucositis in patients with head and neck malignancies. Radiotherapy Oncology 1998;48(S1):S68.
173. Etiz 2000 Etiz D, Erkal HS, Serin M, Kucuk B, Hepari A, Elhan AH, et al.Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncology 2000;36(1):116-20.
174. Evans 1990 Evans G, Mahendra P, Brightwell M, Jestivfe K, Marcus R. A double blind randomised trial of oral GMCFS mouthwash versus placebo in the treatment of mucositis following PBSC/bone marrow transplantation. Bone Marrow Transplantation 1998;21(S1):S88.
175. *Evans WK, Wierzbicki R, Shepherd FA, Rusthoven J, Stewart DJ, Aitken SE, et al.5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. Cancer Investigation 1990;8(3-4):345-9.
176. Evensen 2001 Evensen JF, Bjordal K, Jacobsen AB, Lokkevik E, Tausjo JE. Effects of Na-sucrose octasulfate on skin andmucosa reactions during radiotherapy of head and neck cancers - a randomized prospective study. Acta Oncologica 2001;40(6):751-5.
177. Ezzat 2005 Ezzat M, Shouman T, Zaza K, Safwat A, El-Khoudary A, El-Senosi M, et al.A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. Journal of the Egyptian National Cancer Institute 2005;17(2):85-92.
178. Fahlke 1999 Fahlke J, Ridwelski K, Lippert H. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma. International Journal of Colorectal Disease 1999;14(2):128-30.
179. Falcone 2001 Falcone A, Allergrini G, Masi G, Lencioni M, Panner E, Brunetti I. 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. Oncology 2001;61(1):28-35.
180. Fay 1994 Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH Jr, et al.Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994;84(7):2151-7.
181. Feber 1995 Feber T. Mouth care for patients receiving oral irradiation. Professional Nurse 1995;10(10):666-70.
182. Feber 1996 Feber T. Management of mucositis in oral irradiation. Clinical Oncology 1996;8(2):106-11.
183. Ferreira 2002 Ferreira PR, Fleck J, Filho AB, Barletta D, Barletta A, Diehl A, et al.Protective effect of vitamin E (VE) in head and neck cancer radiation induced mucositis: a double-blind randomized trial. Proceedings of American Society of Clinical Oncology Meeting. 2002:(Abs No 909).
184. Ferreira 2004 Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A, et al.Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head & Neck 2004;26(4):313-21.
185. Ferretti 1985 Ferretti G, Largent B, Brown A, Lillich T, Ash R. The effect of chlorhexidine mouthrinse on mucositis, plaque, gingivitis and stain in bone marrow transplant patients. Journal of Dental Research 1985;64(Special Issue):235 (Abs No 546).
186. Foncuberta 2001 Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG, et al.Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. Journal of Immunotherapy 2001;24(4):384-8.
187. Gabison 1995 Gabison R. Can zinc picolinate in patients receiving chemotherapy formetastatic colorectal carcinoma prevent stomatitis?. European Journal of Cancer 1995;31A(Suppl 5):S258 (Abs No 1234).
188. Giles 2003b Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, et al.Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of Clinical Oncology 2003;21(6):1050-6.
189. Goldberg 2003 Goldberg S. Safety and tolerability of en3247 in the prevention of oral mucositis associated with chemotherapy with or without total body irradiation: results of a randomized, double-blind, placebo-controlled trial. Proceedings of the American Society of Clinical Oncology. 2003:770.
190. Grotz 2001 *Grotz KA, Henneicke-Von Zepelin H-H, Kohnen R, Kutzner J. Belz GG. Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie 2002;23(5): 193-8.
191. Grotz KA, Wustenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin H, Bockisch A, et al.Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer- a prospective, randomized, placebo-controlled, double-blind study. British Journal of Oral and Maxillofacial Surgery 2001;39(1):34-9.
192. Gujral 1999 Gujral MS, Patnaik PM, Kaul R, Daftary GV, Parikh HK, Tamhankar CP, et al.Oral enzymes preventing side effects of radiation therapy in patients with head and neck cancers. European Journal of Cancer 1999;35(Suppl 4):168 (Abs No 634).
193. Gutierrez 1996 Gutierrez AR, Boizas EC, Carreras PS, Rodriguez CS, Rodriguez OA, Chicote MJV, et al.Fluconazol as prophylaxis of radioinduced oral mucositis. Preliminary study [Fluconazol en la profilaxis de la mucositis oral radioinducida. Estudio preliminar]. Oncologia 1996;19(6):56-9.
194. Hanson 1995 Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by misoprostol, a prostaglandin E(1) analog: a placebo-controlled, double-blind clinical trial. American Journal of Therapeutics 1995;2(11):850-7.
195. Hanson 1997 Hanson WR, Marks JE, Reddy SP, Simon S, Mihalo WE, Tova Y. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial. Advances in Experimental Medicine and Biology 1997;400B:811-8.
196. Harris 1995 Harris JR, Russell NH, Hunter AE. Folinic acid mouthwashes do not reduce the degree of mucositis in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 1995;15(S2):S164.
197. Hartmann 1999 Hartmann J, von Vangerow A, Knop S, Brugger W, Fels L, Stolte H, et al.A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors. European Journal of Cancer 1999;35(Suppl 4):361 (Abs No 1464).
198. He 2004 He XY, Hu CS, Wu YR. Radioprotective effect of amifostine in nasopharyngeal carcinoma. Acta Academiae Medicinae Shanghai 2004; Vol. 31, issue 1.
199. Hickey 1982 Hickey AJ, Toth BB, Lindquist SB. Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy. The Journal of Prosthetic Dentistry 1982;47(2):188-93.
200. Howell 1983 Howell SB, Pfeifle CE, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983;51(2):220-5.
201. Hu 2003 Hu K, Ship JA, Harrison LB. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. Seminars in Oncology 2003;30(6 Suppl 18):40-8.
202. Ito 2002 Ito A, Hanawa T, Fujii E. The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs. Gan To Kagaku Ryoho 2002;29(4):563-7.
203. Jebb 1995 Jebb SA, Marcus R, Elia M. A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clinical Nutrition 1995;14:162-5.
204. Johnson 2002 Johnson DJ, Scott CB, Marks JE, Seay TE, Atkins JN, Berk LB, et al.Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07). International Journal or Radiation Oncology Biology and Physics 2002;54(5):1455-9.
205. Kante 1995 Kante V. Comparative study of two prophylactic regimes for the prevention of mucositis in autologous bone marrow transplants. Bone Marrow Transplantation 1995;15:253.
206. Karthaus 1998 Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B, et al.Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplantation 1998;22(8):781-5.
207. Kasten-Sportes 2003 Kasten-Sportes C. Randomized study of acupuncture for mucositis-related pain secondary to high-dose chemotherapy in patients undergoing hematopoietic stem cell transplantation. PDQ (NCI-03-C-0125) 2003.
208. Kenny 1990 Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nursing 1990;13(6):345-53.
209. Klocke 2006 Klocke J, Cannon M, Gissinger D, Bayer R, Devoe C, John V. Prevention of mucositis in auto BMT/stem cell transplant patients. Oncology Nursing Forum 2006;33(2):454.
210. Kokkonen 2002 Kokkonen J, Mottonen M, Karttunen TJ, Lanning M. Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: Vitamin a supplements do not prevent lesions. Pediatric Hematology and Oncology 2002;19(3):181-92.
211. Labar 1990 Labar B, Pavletic Z, Bogdanic V, Nemet D, Aurer I, Jakie J. Prostaglandin E2 for prevention of oral mucositis in patients with leukaemia undergoing bone marrow transplantation: a radomized double-blind clinical trial. Experimental Hematology 1990;18:700.
212. Labbate 2003 Labbate R, Lehn CN, Denardin OVP. Effects of chlorhexidine mouthwash on radiation induced mucosistis in head and neck cancer. Revista Brasileira de Otorrinolaringologia 2003;69(3):349-54.
213. Leong 1995 Leong L, Sakurai C, Sebastian W, Shaw N, Grant E, Grant M, et al.Phase III trial assessing the use of oral thymidine (THY) for prevention of fluorouracil (5-FU)-induced mucositis. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1995; Vol. 14:A334.
214. Levendag 1998 Lavendag PC, Wijers OB, Harms RE, Schmitz PIM, Wilms BE, Visch LL. Mucositis prevention by selective elimination of oral flora in irradiated cancers of the head and neck: a prospective randomized study. Radiotherapy Oncology 1998;48:S10.
215. Levi 1997 Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997;350(9079):681-6.
216. Lievens 1998 Lievens Y, Haustermans K, van den Weyngaert D, van den Bogaert W, Scalliet P, Hutsebaut L, et al.Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy Oncology 1998;47(2):149-53.
217. Lin 2006 Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. International Journal of Radiation Oncology, Biology, Physics 2006;65(3):745-50.
218. Lopez 1994 Lopez I, Goudou C, Ribrag V, Sauvage C, Hazebroucq G, Dreyfus F. Traitement des mucites par la vitamine E lors de l'administration d'anti-neoplasiques neutropeniants. Annuals Medicine Interne 1994;145(6):405-8.
219. Loprinzi 1997 Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC, et al.Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. Journal of Clinical Oncology 1997;15(3):1235-8.
220. Lorusso 2003 Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Annals of Oncology 2003;14(7):1086-93.
221. Lozada 1998 Lozada-Nur F, Schoelch M, Fu K, Muscoplat C, Trivedi M, Smith C, et al.A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the Annual Meeting of the Society of Clinical Oncology. 1998:1541.
222. Madero 1999 Madero L, Diaz MA, Ortega JJ, Olive T, Martinez A, Badell I, et al.Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 1999;84(2):133-7.
223. Mahmoud 1996 Mahmoud HK SE, Kamel M, El HMA, Nassar A. Influence of folinic acid rescue on methotrexate-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Tumor Diagnostik Und Therapie 1996;17(1):18-21.
224. Malaker 1991 Malaker K, Anderson BJ, Beecroft WA, Hodson DI. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detection and Prevention 1991;15(5):335- 40.
225. Mantovani 2003 Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, et al.Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy- induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncology Reports 2003;10(1):197-206.
226. Marcial 1994 Marcial F, Schubert M, Niccoli-Filho WD, Lloid ME, Kelly J, Franquin JC, et al.A phase I/II nonblinded randomized trial to determine the efficacy of low-energy laser to prevent oral mucositis resulting from conditioning regimens for bone marrow transplantation. Oral Surgery, Oral Medicine, Oral Pathology 1994;78(6):738.
227. Masucci 2005 Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, et al.Therapeutic efficacy by recombinant human granulocyte/ monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. Medical Oncology 2005;22(3):247-56.
228. Matejka 1990 Matejka M, Nell A, Kment G, Schein A, Leukauf M, Porteder H, et al.Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. British Journal of Oral Maxillofacial Surgery 1990;28(2):89-91.
229. McGaw 1985 McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouthrinse regimen. Oral Surgery, Oral Medicine, Oral Pathology 1985;60(3):275-80.
230. McIlroy 1996 McIlroy P. Radiation mucositis: a new approach to prevention and treatment. European Journal of Cancer Care 1996;5(3):153-8.
231. Merte 1999 Merte H, Wied R, Engenhart-Cabillic R. Der effekt von immunglobulinen in der behandlung der radiogenen dermatitis und mukositis bei patienten mit hals-nasen und rachentumoren. Strahlentherapy und Onkologie 1999;175(1):135.
232. Mills 1995 Mills W, Strang J, Goldstone AH, Linch DC. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leukemia & Lymphoma 1995;17(3-4):263-70.
233. Minn 1999 Minn HR, Makkonen TA, Jekunen A, Vilja P, Tuominen J, Joensuu H. Granulocyte macrophage-colony stimulating factor (GMCSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. International Journal of Radiation Oncology Biology Physics 1999;45(3 Suppl):239.
234. Nicholl 1995 Nicholl TA, Nimmo CR, Shepherd JD, Phillips P, Jewweson PJ. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions. Annals of Pharmacotherapy 1995;29(11):1081-7.
235. Niibe 1985b Niibe H, Takahashi I, Mitsuhashi N, Miyaishi K, Itoh J, Maehara Y, et al.An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study.2 Abdominal and pelvic tumours. Nippon Gan Chiryo Gakkai Shi 1985;20(5):994-1001.
236. Nikoletti 2005 Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. Journal of Clinical Nursing 2005;14(6):750-3.
237. Ohnmacht 2001 Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, et al.A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2. Journal of Immunotherapy 2001;24(2):188-92.
238. Okuno 1997 Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J, et al.A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 1997;79(1):2193-9.
239. Okuno 1998 Okuno SH, Swan L, Ebbert C. Phase III placebo-controlled clinical trial evaluation of glutamine for decreasing mucositis in patients receiving 5 FU (Fluorouracil)-based chemotherapy. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1998:256.
240. Okutomi 2000 Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, et al.[Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer - prevention of stomatitis and hematopoietic impairment]. Gan To Kagaku Ryoho 2000;27(1):65-71.
241. Papas 1984 Papas A, Johansen E. Prevention of mucositis in oncology patients undegoing radiation therapy. Journal of Dental Research 1984;63(Special Issue March):311 (Abs No 1267).
242. Peters 1993 Peters E, Antczak-Bouckoms A, Burdick E. Meta-analysis of chlorhexidine in the prevention of mucositis from chemotherapy. Journal of Dental Research 1993;Special Issue(259):1249.
243. Peterson 2003 Peterson DE, Petit RG. Phase III study: AES-14 in chemotherapy patients at risk for mucositis. Proceedings of the American Society of Clinical Oncology. 2003:725.
244. Pfeiffer 1989 Pfeiffer P, May O. Sucralfate prophylaxis of chemotherapy-induced stomatitis. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1989.
245. Phillips 2002 Phillips II, GL. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Seminars in Oncology 2002;29(6 Supp 19):53-6.
246. Piccirillo 2003 Piccirillo N, De Matteis S, Laurenti L, Chiusolo P, Sora F, Pittiruti M, et al.Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 2003;88(2):192-200.
247. Porta 1994 Porta C, Moroni M, Nastasi G, Montecucco CM, Caporali R, Notario A. Allopurinol mouthwashes can reduce oral mucositis in chemotherapy-treated patients. Annals of Oncology 1994;5(Suppl 8):208.
248. Pouli 1999 Pouli A, Nikiforakis E. A prospective randomized trial of GM-CFS mouthwash versus sodium bicarbonate mouthwash in the treatment of stomatitis following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1999;23:S166.
249. Prada 1985 Prada A, Lozza L, Moglia D, Sala L, Chiesa F. Effects of benzydamine on radio-polychemotherapeutic mucositis of the oral cavity. International Journal of Tissue Reaction 1985;7(3):237-9.
250. Pyrhonen 1995 Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer 1995;71(3):587-91.
251. Pytlik 2002 Pytlik R, Benes P, Patorkova M, Chocenska E, Gregora E, Prochazka B, et al.Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplantation 2002;30(12):953-61.
252. Rabinovitch 2006 Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, et al.Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head & Neck 2006;28(4):287-96.
253. Rades 2004 Rades D, Fehlauer F, Bajrovic A, Mahlmann B, Richter E, Alberti W. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and Oncology 2004;70(3): 261-4.
254. Radmard 2002 Radmard A, Niewohner-Desbordes U, Wagner W. [rhGM-CSF in the treatment of radiogenic mucositis: prospective randomised phase-II study on the effectivity and tolerance of rhGM-CSF in the treatment of oral mucositis under radiotherapy of head and neck tumors]. Strahlentherapie und Onkologie 2002;178(Suppl 1):24.
255. Raether 1989 Raether D, Walker PO, Bostrum B, Weisdorf D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatric Dentistry 1989;11(1):37- 42.
256. Robustelli 1999 Robustelli della Cuna FS, Ucci G, Cuomo AM, Goglio AM. Galenic preparation for the prophylaxsis of oral mucositis induced by 5-fluororacil continous infusion. Supportive Care in Cancer 1999;7 Suppl: 132 (Abs No P-67).
257. Rocci 2005 Rocci L, Vincenzi B, Santini D, Tonini G. [Timing of 5-fluorouracile infusion: a randomized clinical trial]. International Nursing Perspectives 2005;5(2):53-60.
258. Rojas 2001 Rojas de Morales T, Zambrano O, Rivera L, Navas R, Chaparro N, Bernardonni C, et al.Oral-disease prevention in children with cancer: testing preventive protocol effectiveness. Medicina Oral 2001;6(5):326-34.
259. Rutkauskas 1993 Rutkauskas JS, Davis JW. Effects of chlorhexidine during immunosuppressive chemotherapy: A preliminary report. Oral Surgery, Oral Medicine, Oral Pathology 1993;76(4):441-8.
260. Samaranayake 1988 Samaranayake LP, Robertson AG, MacFarlane TW, Hunter IP, MacFarlane G, Soutar DS, et al.The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation. Clinical Radiology 1988;39(3):291-4.
261. Sato 1997 Sato A, Kumagai S, Sakaki K, Morikawa H, Song ST, Mori S. [Inhibition of 5-fluorouracil-cisplatin-induced stomatitis by oral cryotherapy: use of an ice-bar containing fibrinolysin and deoxyribonuclease comiben (Elase)]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1997;24(9):1135-9.
262. Scarantino 2001a Scarantino CW, LeVeque FG, Scott CB, White RL, Rotman M, Hodson DI, et al.A phase III study of concomitant oral pilocarpine to reduce hypo-salivation and mucositis assocated with curative radiation therapy (RT) in head and neck (H&N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology. 2001:(Abs No 897).
263. Scarantino 2001b Scarantino CW, Leveque F, Scott C, White RL, Rotman M, Hodson DI, et al.A Phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97-09. International Journal of Radiation Oncology, Biology, Physics 2001;51(3 Suppl 1):85-6.
264. Schwerkkoske 1999 Schwerkkoske J, Schwartzberg L, Weaver CH, Schwertschlag US, Goodfellow J, Berdosian CL. A phase I double-masked, placebo-controlled study to evaluate tolerability of Neumega (rhIL-11; Oprelvekin) to reduce mucositis in patients with solid tumors or lymphoma receiving high-dose chemotherapy (CT) with autologous peripheral blood stem cell reinfusion (PBSCT). Proceedings of the American Society of Clinical Oncology. 1999; Vol. 18:584a.
265. Spadaro 1991 Spadaro P, Buemi B, Ferraro G, Marabello G, Russi E, Pergolizzi S. Prophylaxis of chemotherapy-radiotherapy induced mucositis or oral fungal infection with vitamin E + vitamin A and Fluconazolo. European Journal of Cancer 1991;27(Suppl 2):S288.
266. Staar 2001 Staar S. Benefits and toxicities of accelerated radiochemo- versus accelerated radiotherapy in advanced head and neck cancer - Results of a German randomized study. European Journal of Cancer 2001;37(Suppl 6):38 (Abs No 126).
267. Stokman 2004 Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, et al.Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study. Anticancer Research 2004;24(5B):3263-7.
268. Su 2004a Su C, Mehta V, Ravikumar L, Shah R, Pinto H, Halpern J, et al.Phase II double-blind randomized study comparing oral aloe vera (AV) versus placebo to prevent radiation (RT)-related mucositis in patients with head and neck (HN) neoplasms. Proceedings of the Amercian Society of Clinical Oncology. 2004.
269. Su 2004b Su YB. Double-blind, randomized trial of granulocyte-colony stimulating factor (GCSF) versus (v.) placebo during postoperative radiation (RT) for advanced resectable squamous cell head and neck cancer (SCCHN): impact on mucositis. Journal of Clinical Oncology 2004;22(Suppl):14S.
270. Suc 1999 Suc A, Gandemer V, Le Deley MC, Schmitt C, Pichard-Leandri E, French Group. Gum98: Preventing mucositis with chewing gum in children receiving chemotherapy, amulticentric trial. Supportive Care in Cancer 1999;7S:180 (Abs No P-60).
271. Svanberg 2004 Svanberg A, Öhrn K. Cryotherapy during chemotherapy - could it delay or alleviate the development of mucositis?. Bone Marrow Transplantation 2004;33(Suppl 1):S292.
272. Sykes 2004 Sykes AJ, Slevin NJ, MacDougall RH, Ironside JAD, Mais KL. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 2004;71(1):81-4.
273. Symonds 1995 Symonds RP, Thomas M, Alcock SR, Khorrami J, McEllroy P, McMuuuray A. The reduction of radiation mucositis by antibiotic pastilles: a placebo-controlled double-blind trial. European Journal Surgery Oncology 1995;21:447.
274. Teshima 1986 Teshima T. [Clinical evaluation of kenalog ointment for radiation mucositis of patients with head and neck cancer]. Yakuri to Chiryo (Japanese Pharmacology and Therapeutics) 1986;14(11):7163-6.
275. Thieblemont 2002 Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Arnaud P, et al.Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 2002;30(11):769-75.
276. Throuvalas 1995 Throuvalas N, Antonadou D, Pulizzi M, Sarris G. Evaluation of the efficacy and safety of GM-CSF in the prophylaxis of mucositis in patients with head and neck cancer treated with RT. European Journal of Cancer 1995;31(Suppl 5):S93 (Abs No 431).
277. Toubai 2003 Toubai T, Tanaka J, Fujisawa F, Kondo Y, Imamura M, Ota S, et al.Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole. Japanese Journal of Antibiotics 2003;56(1):61-5.
278. Uchiyama 2005 Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Furukawa S. Effectiveness of Cepharanthin in decreasing interruptions during radiation therapy for oral cancer. Oral Radiology 2005;21(1):41-4.
279. Vacha 1999 Vacha P, Marx M, Engel A, Richter E, Feyerabend T. Side effects of postoperative radiochemotherapy with amisfostine versus radiotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial [Nebenwirkungen einer posoperativen radiochemotherapie mit amifostin versus alleiniger radiochemotherapie bei kopf-hals-tumoren. Vorlaufige ergebnisse einer prospektiv randomisierten untersuchung]. Strahlentherapie und onkologie 1999;175(S4):18-22.
280. Vacha 2003 Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, et al.Randomized phase III trial of postoperative radiochemotherapy amifostine in head and neck cancer: Is there evidence for radioprotection?. Strahlentherapie und Onkologie 2003;179(6):385-9.
281. Valcarcel 2002a Valcarcel D, Sanz M, Sureda A, Sala M, Munoz L, Subira M, et al.Topically applied recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for oropharyngeal mucositis (OM) in stem cell transplantation recipients: a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;Suppl 2:S20.
282. Valcarcel 2002b Valcarcel D, Sanz MA Jr, Sureda A, Sala M, Munoz L, Subira M, et al.Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplantation 2002;29(9):783-7.
283. Valcárcel 1997 Valcárcel F, De la Torre A, Aragón G, Lanzós E, Rodríguez R, Veiras C. Double-blind randomized and pilot study on the potential of thymostimulin to reduce the incidence of mucositis in head and neck cancer patients with radical radiotherapy. Oncología IX Congreso Nacional de la Asociación Española de Radioterapia y Oncología. 1997; Vol. 20:161.
284. van Zaanen 1994 van Zaanen HC, van der Lelie H, Timmer JG, Furst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer 1994;74(10):2879- 84.
285. Verdi 1995 Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxiflline for the prevention of chemotherapy-induced oral mucositis. Osomopore 1995;80(1):36-42.
286. Vesole 1999 Vesole D, Fuchs HJ. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy. Blood 1999;94(10 Suppl 1):154 (Abs No 675).
287. Vitello 2000 Vitello M, Cianio SG. A comparison of two mouthrinse agents used during head/neck radiation. Journal of Dental Research 2000;79(Special Issue):215 (Abs No 576).
288. Wagner 2002 Wagner W, Radmard A, Niewohner-Desbordes U, Haus U, Matt J. rhGM-CSF in the treatment of radiotherapy induced mucositis-prospective randomized, double-blind study to investigate the feasibility and effectiveness of rhGM-CSF in patients with head and neck cancer. Proceedings of the American Society for Therapeutic Radiology and Oncology Meeting. 2002:311 (Abs No 2175).
289. Wang 2002b Wang HM, Wang CS, Chen JS, Chen IH, Liao CT, Chang TC. Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;94(11):2989-95.
290. Warde 2002 Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J, et al.A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology and Physics 2002;54(1):9-13.
291. Weisdorf 1989 Weisdorf DJ, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B, et al.Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouthrinse. Bone Marrow Transplantation 1989;4(1):89-95.
292. Weiss 1990 Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, et al.A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial. Gynecologic Oncology 1990;37(3): 354-8.
293. Whelan 2002 Whelan HT, Connelly JF, Hodgson BD, Barbeau L, Post AC, Bullard G, et al.NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. Journal of Clinical Laser Medicine & Surgery 2002;20(6):319-24.
294. Whelan 2004 Whelan H. Phase II randomized study of NASA-developed light-emitting diode therapy for the prevention of oral mucositis in children receiving amyeloablative conditioning regimen comprising chemotherapy with or without radiotherapy followed by first allogeneic bone marrow transplantation. http://www.clinicaltrials.gov (accessed 2003).
295. Wollina 2002 Wollina U, Christen N, Kostler E, Schorcht J. On prophylaxis and treatment of radiation-induced dermatitis and mucositis. Zeitschrift fur Hautkrankheiten 2002;77(9):418-23.
296. Wymenga 1999a Wymenga AN, van der Graaf WT, Hofstra LS, Timens W, Spijkervet FK, Hospers GAP, et al.TGF-b3 mouthwashes aimed at prevention of chemotherapy induced mucositis, a phase-I study. Supportive Care in Cancer 1999;7:168.
297. Wymenga 1999b Wymenga AN, van der Graaf WT, Hofstra LS, Spijkervet FK, Timens W, Timmer-Bosscha H, et al.Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. Clinical Cancer Research 1999;5(6):1363-8.
298. Yokomizo 2004 Yokomizo H, Yoshimatsu K, Hashimoto M, Ishibashi K, Umehara A, Yoshida K, et al.Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. Anticancer Research 2004;24(2C):1131-4.
299. Zalcberg 1995 Zalcberg J, Cunningham D, Rath U, Olver I, Kerr D, van Cutsem E, et al.'Tomudex' (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-Fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): first results of a phase III study. European Journal of Cancer 1995;31f:S146 (Abs No 701).
300. Haddad 2003 Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/ paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in Oncology 2003;30(6 Suppl 18):84-8.
301. Andreassen 2003 Andreassen CN, Grau C, Lindegaard JC. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Seminars in Radiation Oncology 2003;13(1):62-72.
302. Barasch 2003 Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncology 2003;39(2):91-100.
303. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al.Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276(8):637-9.
304. Bellm 2002 Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T, et al.Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Investigation 2002;20(5-6):793-800.
305. Chang 2003 Chang VT, Ingham J. Symptom control. Cancer Investigation 2003;21(4):564-78.
306. Clarkson 2004 Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment.Cochrane Database of Systematic Reviews 2004, Issue 1.Art. No.: CD1972. DOI:10.1002/14651858.CD1972.pub2.
307. Clarkson 2007a Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD003807. DOI:10.1002/14651858.CD003807.pub3.
308. Clarkson 2007b Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2007, Issue 2.Art. No.: CD001973. DOI:10.1002/14651858.CD001973.pub3.
309. De Pauw 1997 De Pauw BE. Practical modalities for prevention of fungal infections in cancer patients. European Journal of Clinical Microbiological Infectious Diseases 1997;16(1):32-41.
310. Denning 1992 Denning DW, Donnelly JP, Hellreigel KP, Ito J, Martino P, van't Wout JW. Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art?. Chemotherapy 1992;38(S1):43-9.
311. Duncan 2003 Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Alimentary Pharmacology Therapeutics 2003;18:853-74.
312. Elbourne 2002 Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials. International Journal of Epidemiology 2002;31(1):140-9.
313. Gotzsche 1999 Gotzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews 1999, Issue 2.Art. No.: CD000026. DOI:10.1002/14651858.CD000026.
314. J Briggs Inst 1998 Joanna Briggs Institute. Prevention and treatment of oral mucosistis in cancer patients. Best Practice: evidence based practice information sheets for health professionals 1998; Vol. 2, issue 3:1-6.
315. Kowanko 1998 Kowanko I, Long L, Hodgkinson B, Evans D. The effectiveness of strategies for preventing and treating chemotherapy and radiation induced oral mucositis in patients with cancer. Joanna Briggs Institute for Evidence Based Nursing and Midwifery 1998:1-84.
316. Lortholary 1997 Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clinical Microbiological Review 1997;10(3):477-504.
317. McGuire 2004 McGuire DB, Rubenstein EB, Peterson DE. Evidence-based guidelines for managing mucositis. Seminars in Oncology Nursing 2004;20(1):59-66.
318. Meunier 1994 Meunier F, Paesmans M, Autier P. Values of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients. Oral Oncology, European Journal of Cancer 1994;30B(3): 196-9.
319. Moher 2001 Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Annals of Internal Medicine 2001;134(8):657-62.
320. Rubenstein 2004 Rubestein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al.Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer Supplement 2004;100(9):2026-46.
321. Savarese 2003 Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treatment Reviews 2003;29(6):501-13.
322. Sonis 2004 Sonis ST, Elting LS, Keefe D, Peterson ED, Schubert M, Hauer-Jensen M, et al.Perspectives on cancer therapy-induced mucosal injury. Cancer Supplement 2004;100(9):1995-2025.
323. Stevens 1995 Stevens DA. Therapy for opportunistic fungal infections: past present and future. Indian Journal of Cancer 1995;32(1):1-9.
324. Stokman 2006 Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG. Preventive intervention possibilities in radiotherapy-and chemotherapy-induced oral mucositis: results of meta-analyses. Journal of Dental Research 2006;85(8):690-700.
325. Sunderland 2001 Sutherland SE, Browman GP. Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. International Journal of Radiation Oncology, Biology and Physics 2001;49(4):917-30.
326. Symonds 1998 Symonds RP. Treatment-induced mucositis: an old problem with new remedies. British Journal of Cancer 1998;77(10): 1689-95.
327. Verdi 1993 Verdi CJ. Cancer therapy and oral mucositis. Drug Safety 1993;9(3):185-95.
328. White 1993 White M. Antifungal prophylaxis. Current Opinion in Infectious Diseases 1993;6:737-43.
329. Worthington 2004a Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2004, Issue 2.Art. No.: CD001973. DOI:10.1002/14651858.CD001973.pub2.
330. Worthington 2004b Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2004, Issue 4.Art. No.: CD003807. DOI:10.1002/14651858.CD003807.pub2.
331. Worthington 2007 Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2007, Issue 2.Art. No.: CD001972. DOI:10.1002/14651858.CD001972.pub3.
332. Wright 2003 Wright JR, McKenzie M, DeAngelis C, Foroudi F, Paul N, Rajaraman M, et al.Radiation induced mucositis: co-ordinating a research agenda. Clinical Oncology 2003;15(8):473-7.
333. Clarkson 2000 Clarkson JE, Worthington HV, Eden OB. Prevention of oral mucositis or oral candidiasis for patients with cancer receiving chemotherapy (excluding head and neck cancer). Cochrane Database of Systematic Reviews 2000, Issue 2.
334. Clarkson 2003a Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2003, Issue 3.Art. No.: CD000978. DOI:10.1002/14651858.CD000978.
335. Worthington 2006 Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2006, Issue 2.Art. No.: CD000978. DOI:10.1002/14651858.CD000978.pub2.